Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Inrebic (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Spleen Volume Reduction and Total Symptom Score Reduction in Myelofibrosis: Fedratinib and ruxolitinib were confirmed as effective for spleen volume reduction and symptom score reduction in a systematic review and network meta-analysis of 1953 patients. Momelotinib showed comparable efficacy to ruxolitinib, with reduced toxicity in erythrocytes and platelets.
• Mortality and Clinical Improvement in COVID-19: The meta-analysis of 1190 hospitalized COVID-19 patients indicated that JAK inhibitors, including fedratinib, were associated with a reduced risk of mortality (OR 0.51) and improved clinical outcomes (OR 1.76).
• Fedratinib and ruxolitinib exhibited distinct tolerance profiles, with Momelotinib showing a favorable effect on anemia. Pacritinib demonstrated higher toxicity concerning erythrocytes and platelets compared to Momelotinib in myelofibrosis patients.
• The safety outcomes were not explicitly discussed in the study on COVID-19 treatment, and no comparative safety analysis among the JAK inhibitors was provided.
• There is no population or subgroup information available in the reviewed studies.